# The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

> **NCT04104607** · PHASE1 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 86 (estimated)

## Conditions studied

- Castration-Resistant Prostatic Cancer

## Interventions

- **DRUG:** CC-1, PSMAxCD3

## Key facts

- **NCT ID:** NCT04104607
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104607, "The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04104607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*